D
Lantern Pharma Inc. LTRN
$3.93 $0.133.42%
Recommendation
Sell
Prev Close
$3.93
Volume
20
Avg Vol (90D)
85,660
Market Cap
$42.38M
Dividend & Yield
--
52-Week Range
$2.79 - $11.99
P/E (TTM)
--
EPS (TTM)
-$1.78
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
BIOS Capital Management LP Buys Shares of 1,207,709 Lantern Pharma Inc. (NASDAQ:LTRN)
3/17/2025 - Ticker Report
Will Lantern Pharma (NASDAQ:LTRN) Spend Its Cash Wisely?
2/21/2025 - Simply Wall St
Lantern Pharma (LTRN) Files Patent for AI-Powered Blood-Brain Barrier Prediction Tech
2/20/2025 - Insider Monkey
10 AI News and Ratings You Should Not Miss
2/20/2025 - Insider Monkey
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, ...
2/19/2025 - GuruFocus
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
2/19/2025 - Business Wire
Lantern Pharma Inc. (NASDAQ:LTRN) Shares Sold by DAVENPORT & Co LLC
2/10/2025 - Ticker Report
Lantern Pharma Inc. (LTRN) Enhances RADR AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies
1/27/2025 - Insider Monkey
Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development
1/17/2025 - Insider Monkey
Complete List of All AI Companies Under $2 Billion Market Cap
1/17/2025 - Insider Monkey
AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan
12/10/2024 - Insider Monkey
10 AI News That Broke The Internet
12/10/2024 - Insider Monkey
Lantern Pharma doses first patient in LP-300 trial
12/9/2024 - The Fly
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
12/9/2024 - Business Wire
Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer
12/7/2024 - Insider Monkey
15 AI News Updates That Broke The Internet
12/6/2024 - Insider Monkey
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation ...
12/3/2024 - GuruFocus
Lantern Pharma granted fast track designation for LP-184
12/3/2024 - TipRanks Financial Blog
Lantern Pharma granted fast track designation for LP-184
12/3/2024 - The Fly
Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC)
12/3/2024 - Business Wire
Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
11/26/2024 - Business Wire
Lantern Pharma doses first patient in LP-300 trial expansion cohort
11/19/2024 - The Fly
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
11/19/2024 - Business Wire
Lantern Pharma (NASDAQ:LTRN) Furnishes Presentation for Recent Conference Call and Webinar, Updates Financial Results
11/12/2024 - Ticker Report
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$21.18M
EBIT (TTM)
-$21.20M
Net Income (TTM)
-$19.09M
Balance Sheet
Total Assets (Q)
$30.29M
Total Debt (Q)
$291.20K
Total Liabilities (Q)
$3.70M
Book Value Per Share (Q)
$2.47
Cash Flow
Cash from Operations (TTM)
-$17.23M
Cash from Investing (TTM)
$178.20K
Cash from Financing (TTM)
-$433.30K
Net Change in Cash (TTM)
-$17.47M
Filings
Filing Date
Thursday, November 7, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 17 and 21 (est)
Price History
Loading...
Beta
2.11
7-Day Total Return
7.38%
30-Day Total Return
-15.85%
60-Day Total Return
14.58%
90-Day Total Return
19.82%
Year to Date Total Return
19.09%
1-Year Total Return
-60.54%
2-Year Total Return
-15.48%
3-Year Total Return
-43.53%
5-Year Total Return
--
52-week Low
Nov 21, 2024 - $2.79
52-week High
Mar 25, 2024 - $11.99
Valuation
Market Cap
$42.38M - Nano Cap
Enterprise Value
$14.62M
Price/Sales (TTM)
--
Price/Book (Q)
1.59
Dividends and Shares
Shares Outstanding
10.76M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.lanternpharma.com
Phone Number
972 277 1136
Address
1920 McKinney Avenue
Dallas, TX 75201
Country
United States
Year Founded
2013
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product... more
NASDAQ 03/17/2025 3:59PM Eastern Quotes delayed
Weiss Ratings